CD276 and neoplasm: Compared with alisertib or anti–B7-H3 mAb monotherapy, alisertib combined with anti–B7-H3 mAbs had a synergistic inhibitory effect on tumor growth (Figure 8, B–D, and Supplemental Figure 4D).